S

Sobi

Develops therapies for rare diseases

PV Partnership & Operations Director

Full-TimeUpdated on 10/23/2026
No salary listed
Expert
Bachelor's
Basel, Switzerland
Hybrid
Biology & Biotech

About the job

Requirements
  • A university-level qualification in biosciences, healthcare, or pharmacy is required.
  • At least 10 years of relevant pharmacovigilance experience within the pharmaceutical industry, including strong experience in case processing, clinical study safety data management, partner and vendor oversight, and applicable Good Pharmacovigilance Practices, Good Clinical Practice, and global regulatory requirements.
  • Experience leading and developing teams, including effective people management, supervision, capability building, and prioritisation of work in a complex operational environment.
  • Thorough knowledge of Good Pharmacovigilance Practices and Good Clinical Practice is required.
  • Fluency in written and spoken English is required.
  • Strong organisational, planning, prioritisation, and problem-solving skills are required.
  • The candidate must be able to work effectively to deliver ambitious goals.
  • The candidate must be able to prepare, empower, and support an assigned team across its broad range of deliverables.
  • The candidate must be able to work collaboratively in internal and external cross-functional settings and matrix teams.
  • The candidate must be a proactive, independent, and collaborative problem-solver, with the judgement, determination, and courage to resolve or escalate issues appropriately, drive collaborative assessment and solution development, and implement solutions to complex cross-functional and cross-company problems.
  • The candidate must be able to build strong relationships and collaborate within pharmacovigilance and across the wider organisation.
  • The candidate must communicate clearly, distil large amounts of information to identify root causes, and propose appropriate actions.
  • The candidate must exercise sound and balanced judgement, assess and manage risks, and be self-confident, proactive, and decisive.
Responsibilities
  • Lead the PV Partnership & Operations function by assigning and coordinating activities across the team and setting strategic direction, priorities, the operating model, governance structures, and performance expectations.
  • Provide overall accountability for the function’s activities, deliverables, quality, compliance, risk management, performance monitoring, and inspection readiness, and highlight concerns to GPV Management.
  • Lead, develop, and oversee the PV Partnership & Operations team, including resource management, recruitment, performance management, capability building, coaching, escalation support, and succession planning.
  • Provide PV functional leadership for new and existing Sobi partner collaborations, including alliance leadership, operational activities, PV process alignment, governance meetings, and escalation processes.
  • Ensure partner and distributor obligations under PVAs and SDEAs are clearly defined, implemented, and fulfilled.
  • Oversee case-exchange elements in Pharmacovigilance Agreements and Safety Data Exchange Agreements, including oversight and reconciliation; identify delivery gaps and develop and deliver corrective actions.
  • Maintain oversight of case-exchange quality, timeliness, completeness, and reconciliation, ensuring discrepancies are investigated and resolved appropriately.
  • Work with the PV VM team and, through that team where applicable, with Sobi PV eESPs to understand performance and quality concerns and develop and implement corrective actions.
  • Work with the ODT Tech lead and OSIRIS Config team to ensure appropriate configuration for products, clinical trials, and marketing authorisations.
  • Lead development of, and hold overall accountability for, study-level Safety Management Plans across Sobi functions and external service providers, ensuring clear roles and responsibilities and delivery and quality expectations for case management and safety reporting within clinical studies.
  • Be accountable for study training of the case-processing vendor.
  • Oversee collaboration with Clinical Operations, Global Regulatory Affairs, Contract Research Organisations, Clinical Data Management, and other stakeholders to ensure appropriate transfer, reconciliation, and reporting of safety data.
  • Be accountable for preparation, approval, and maintenance of product-level case-processing Product Safety Information guides, and appropriately assess Market Research and Patient Support Program materials for pharmacovigilance impact.
  • Work with GPV Excellence, Sobi QA, PV VM, other Sobi functions, and external vendors to ensure quality and compliance standards are defined and maintained for partner-related PV activities.
  • Ensure quality and compliance of PV Partnership & Operations activities, including proactive identification and management of operational, quality, and compliance risks.
  • Work with Safety Science Leads to ensure individual case safety data are of appropriate quality to support aggregate reporting and signal management, and provide feedback and appropriate corrective measures to the case-processing vendor.
  • Act as the senior subject matter expert for audits and inspections relating to PV Partnership & Operations activities.
  • Oversee non-conformance investigations, corrective and preventive actions, issue escalation, inspection readiness, and preparation, coordination, and follow-up of relevant audits and regulatory inspections.
  • Ensure new or changed PV partnerships, study or product activities that affect the Sobi PV system and PV vendor operations are flagged and addressed by the responsible teams, including Sobi PV VM and the Osiris Configuration team.
  • Work with responsible functions to ensure systems are set up and functioning appropriately to meet Sobi GPV PV commitments.
  • Lead the PV Partnership team’s contribution to company acquisitions, product integrations, and other business development activities affecting the Sobi PV system, including future PV operating-model contributions, alignment of roles and responsibilities between Sobi PV and partners, PV data migration design and delivery, product and activity integration into the PV system, and PV system configuration and operational readiness across products.
  • Oversee the respective PV Partnership Manager’s design, setup, operation, and closeout of the PV system supporting Sobi-sponsored clinical studies and ISSs.
  • Be accountable for the Drug Safety inbox and ensure continued team oversight and coverage.
  • Serve as the senior functional interface between PV Operations, Safety Science, and relevant Sobi business functions on product-specific and process-related matters, such as case-processing questions.
Desired Qualifications
  • Working knowledge of IQVIA Vigilance Platform is desired.
  • Previous international or global people-management experience is desired.

About the company

Sobi specializes in developing and delivering therapies for rare diseases. It focuses on hematology, immunology, and specialty care, bringing medicines to patients who have limited treatment options. Their products are designed to treat rare conditions and are typically administered by prescription under medical supervision; the company collaborates with partners to advance research, develop, and commercialize these therapies. Sobi differentiates itself through its strong biotechnological foundation from its Biovitrum heritage and a track record of strategic collaborations with major pharmaceutical players like Sanofi and Apellis, which expand its research capabilities and reach. The company’s goal is to improve the lives of patients with rare diseases worldwide by creating and delivering effective treatments that address unmet medical needs.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Solna kommun, Sweden

Founded

1988

Get referred to Sobi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • EMA validated Tryngolza sHTG filing in March 2026, de-risking the European expansion path.
  • Aspaveli’s EU enFuse launch broadened home use, and Q1 2026 revenue rose 24%.
  • Arthrosi’s 2026 Phase 3 readouts can unlock a large gout market and justify premium valuation.

What critics are saying

  • Guido Oelkers leaves by January 2027, risking launch disruption during a pivotal year.
  • Tryngolza’s sHTG EU decision waits until 2027, delaying a major revenue expansion.
  • High debt and launch spending pressure margins if Aspaveli, Tryngolza, or pozdeutinurad disappoint.

What makes Sobi unique

  • Sobi owns rare-disease franchises across hematology, immunology, nephrology, and gout globally.
  • Tryngolza, Aspaveli, and Altuvoct create a multi-launch portfolio, not one-asset dependence.
  • Arthrosi adds pozdeutinurad, giving Sobi a late-stage gout platform and commercial rights.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Company Match
  • Tuition Reimbursement
  • Wellness Program

Growth & Insights and Company News

6 month growth

10%

1 year growth

10%

2 year growth

10%
Associated Press
Oct 1st, 2026
NICE recommends Tryngolza for ultra-rare lipid disorder treatment in England and Wales

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending Tryngolza (olezarsen) for treating genetically confirmed familial chylomicronaemia syndrome (FCS) in adults in England and Wales. The treatment is approved only when diet and conventional triglyceride-lowering treatments prove inadequate. FCS is an ultra-rare inherited lipid disorder characterised by severe hypertriglyceridaemia and increased risk of acute pancreatitis. Around 114 people in the UK are diagnosed with FCS, though the condition is thought to be under-diagnosed. The recommendation follows positive Phase 3 Balance study results, where Tryngolza 80 mg demonstrated statistically significant reductions in fasting triglyceride levels at six months, sustained through 12 months. The treatment also showed clinically meaningful reductions in acute pancreatitis events. Sobi UK holds exclusive commercialisation rights for Tryngolza outside the US, except Canada and China.

Nu Pagamentos S.A. (Nubank)
Aug 7th, 2026
Swedish pharma Sobi acquires full control of Latin American oncology specialist Pint Pharma

Swedish biopharmaceutical company Sobi (Swedish Orphan Biovitrum) is acquiring full ownership of Pint Pharma, a firm specialising in bringing complex treatments, including cancer therapies, to Latin American markets. The transaction builds on Sobi's initial investment last year, when it paid $105 million for most of Pint's economic rights. The deal, submitted to Brazil's competition authority Cade, involves purchasing all remaining shares of Pharma Investments, Pint's parent company. The transaction value remains undisclosed. The acquisition gives Sobi control of a platform operating across seven Latin American markets, including Brazil, Mexico, Argentina, and Colombia. Pint handles regulatory approval, market access, and distribution of specialised medicines for rare diseases, haematology, and oncology. Sobi reported revenue of 28.2 billion Swedish kronor (approximately $2.9 billion) in 2025. The companies have maintained a commercial partnership since 2021.

Yahoo Finance
Aug 3rd, 2026
Swedish biopharma Sobi CEO Guido Oelkers to step down by January 2027

Swedish biopharma firm Sobi announced that chief executive Guido Oelkers will step down to take up another position outside the company. Oelkers will continue in his role until the end of January 2027 at the latest. "Leading Sobi has been a privilege, and I am proud of what we have accomplished together as a team," Oelkers said. He highlighted advancing the pipeline, expanding global footprint, and growing Sobi into a leader in rare diseases. The company will immediately begin searching for a new chief executive. Sobi's operations, strategy, and financial targets remain unchanged, the firm said.

PR Newswire
Jul 15th, 2026
Sobi repurchases shares at $0.05 to secure employee incentive programme commitments

Swedish Orphan Biovitrum (Sobi) is repurchasing shares to support its employee incentive programme. The Board of Directors exercised authorisation granted at the May 2026 Annual General Meeting to repurchase class C shares at approximately SEK 0.55 per share, representing 100% of their quotient value. The repurchase involves 223,677 shares and will occur between 16 July and 6 November 2026. Svenska Handelsbanken will handle the transaction. After converting the repurchased class C shares to common shares, Sobi will hold 10,290,974 own shares. The move secures commitments under the All Employee Programme, a long-term incentive scheme for permanent staff. Sobi, a biopharma company focused on rare diseases, employs approximately 2,000 people globally and reported revenue of SEK 28 billion in 2025.

Associated Press
May 22nd, 2026
Enable Injections' enFuse on-body delivery system receives CE certification for Aspaveli in EU

Enable Injections has received CE Certification for its enFuse On-Body Delivery System for use with Aspaveli (pegcetacoplan), which will be distributed by Swedish Orphan Biovitrum across the European Union as ASPAVELI enFuse. The certification allows caregivers and patients aged 12 and older to use the wearable device for subcutaneous drug administration. The enFuse system delivers medication through a discreet, hands-free device using a small, hidden needle, designed to improve patient self-administration. Aspaveli is approved for treating paroxysmal nocturnal haemoglobinuria, C3G and primary IC-MPGN in patients 12 years and older. This follows recent regulatory clearances in Saudi Arabia, Brazil, South Korea and Canada, part of Enable's strategic partnership with Sobi announced in September 2024.